drugset / Trial / NCT00501605
Phase I Study With AZD2171 in Patients With Advanced Solid Malignant Tumors and Liver Metastases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Single centre recruiting approximately 80 patients who are given a rising single, followed by multiple, ascending oral dose of AZD2171, assessing the safety and tolerability of AZD2171 in patients with solid tumors and metastatic liver disease.
Timeline
- Start
- 2003-02
- Primary completion
- 2005-04
- Completion
- 2006-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | — | Oral |